Medicare to cover expensive cancer treatments

July 2011
PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11
The article reports on the plan of Medicare to cover Avastin bevacizumab for breast cancer treatment regardless of the decision of the U.S. Food and Drug Administration (FDA) to rescind Avastin approval for such indication in July 2011.


Related Articles

  • Avastin Gets More Time for Review.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article accounts on the report issued by the U.S. Food and Drug Administration regarding the extension of the review period for Avastin, a drug used to treat cancer including cancer of the breast, lungs, colon, brain, and kidneys.

  • Most Doctors Back Avastin Withdrawal.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93 

    The article reports on the support of fifty-eight percent of physicians in a poll by Sermo, on the move of the Food and Drug Administration (FDA) to pull the breast cancer indication for Avastin from the market.

  • Oh Those Death Panels. Penza, Logan // Moderate Voice;8/16/2010, p8 

    The article offers the author's insights on the death panel label given by critics to the health care reform boards who decide on what possible life-saving processes or drugs would deserve funding. It notes that the label has a bit of reality as the Food and Drug Administration (FDA) considers...

  • TOP STORIES.  // Ocular Surgery News;5/10/2015, Vol. 33 Issue 9, p22 

    The article lists the most viewed news in the website Healio.com/OSN between March 28 and April 13, 2015 including the concern of the U.S. Food and Drug Administration (FDA) on cross-linking system, the controversy on the use of bevacizumab, and the audio recording of the consultation.

  • Dutasteride and Low-Risk Prostate Cancer. Elliott, William T. // OB/GYN Clinical Alert;Mar2012 Pharmacology, p1 

    The article discusses the usage of dutasteride and bevacizumab in the treatment of prostate cancer and in breast cancer, respectively. Information is presented on the U.S. Food and Drug Administration's rule regarding the drugs cephalosporins, exenatide and vismodegib. As stated, the U.S....

  • Learn Everything You Need to Know About the FDA--Join the Audio Conference October 10.  // O&P Almanac;Aug2012, Vol. 61 Issue 8, p47 

    The article offers information on the AOPAversity Mastering Medicare Audio Conference to be held on October 10, 2012 which will cover what facility needs to know on the U.S. Food and Drug Administration (FDA).

  • Pharmacy foes. Conlan, Michael F. // Drug Topics;8/4/97, Vol. 141 Issue 15, p71 

    Reports that drug firms in the United States are opposed to care policies proposed in a MedGuide program by the Food and Drug Administration. Details on the policies; Why drug firms oppose the policies; Other information on the controversy.

  • Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time? Mandock, Katherine; Soefje, Scott A.; Adams, R. // Journal of Hematology Oncology Pharmacy;Dec2011, Vol. 1 Issue 4, p6 

    The article focuses on the U.S. Food and Drug Administration's (FDA) decision to remove bevacizumab's current labeled indication for metastatic breast cancer (MBC). Postapproval trials required with the FDA approval for bevacizumab for treatment did not demonstrate an overall survival (OS)...

  • Fighting Fire with Fire: Rekindling the Bevacizumab Debate. Montero, Alberto J.; Vogel, Charles // New England Journal of Medicine;1/26/2012, Vol. 366 Issue 4, p374 

    The article discusses the controversy concerning the decision of the U.S. Food and Drug Administration (FDA) to revoke bevacizumab approval in 2012. It says that the agency opposed the use of the substance when combined with paclitaxel to treat patients with metastatic breast cancer. According...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics